Myasthenia Gravis Overview

Myasthenia Gravis Overview

  • Definition: Myasthenia gravis (MG) is a chronic disorder of the neuromuscular junction characterized by antibodies (IgG) that block acetylcholine (ACh) receptors, inhibiting nerve impulse transmission.

  • Primary Symptoms: The disorder is characterized by muscle fatigue and weakness that typically improves after rest.

  • Severe Cases: Can lead to respiratory muscle paralysis, known as a myasthenic crisis.

Neuromuscular Junction and Impairments

  • Normal Neuromuscular Junction:

    • Involves the transmission of nerve impulses from neuron to muscle via ACh, which binds to receptors on muscle fibers, leading to contraction.

  • Myasthenia Gravis Effect:

    • In MG, antibodies block ACh receptors, resulting in reduced transmission and impaired muscle contraction.

Anatomic Alterations Associated with Ventilatory Failure

  • Conditions contributing to ventilatory failure include:

    • Mucous accumulation

    • Airway obstruction

    • Alveolar consolidation

    • Atelectasis

Types of Myasthenia Gravis

  • Ocular Myasthenia Gravis:

    • Muscle weakness is limited to eyelids and extraocular muscles.

  • Generalized Myasthenia Gravis:

    • Muscle weakness may involve:

    • Bulbar muscles responsible for speech and swallowing.

    • Limbs and respiratory muscles.

    • May or may not involve ocular muscles.

    • Key point: Sensory function remains intact.

Etiology and Epidemiology

  • Common Demographics:

    • Most prevalent in young women aged 15-35 and older men aged 40-70.

  • Provoking Factors:

    • Emotional upset

    • Physical stress

    • Extreme temperature changes

    • Febrile illness

    • Pregnancy

Screening and Diagnosis

  • Clinical Presentation & History: Key to identifying MG.

  • Bedside Tests:

    • Edrophonium Test: Previously used, no longer in use.

    • Ice Pack Test: 5-minute application can improve ptosis (drooping eyelids).

    • Sleep Test: Improvement in ptosis after sleep indicates potential MG.

  • Immunologic Studies: Blood analysis for elevated ACh receptor antibodies.

  • Electrodiagnostic Studies:

    • Repetitive nerve stimulation

    • Electromyography (EMG)

  • Imaging: CT or MRI to detect thymoma (benign thymus tumor).

  • Differential Diagnosis: Necessary to rule out other diseases.

  • Pulmonary Function Tests: Assess ventilatory failure status.

Clinical Presentation

  • Facial Muscle Weakness: Includes ptosis, diplopia (double vision), and ophthalmoplegia (paralysis/weakness of eye movement).

  • Additional Symptoms:

    • Difficulty breathing, speaking, chewing, and swallowing.

    • Unstable gait.

    • Weakness in arms, hands, fingers, legs, and neck, often exacerbated by repetitive motions (reason: muscle fatigue).

    • Potential for descending paralysis (termed "Mind to Ground").

Edrophonium Test

  • Historical Background:

    • Used for MG diagnosis; FDA discontinued in 2018 due to safety concerns.

    • Mechanism: Injection of edrophonium prevents ACh breakdown, increasing ACh concentration, alleviating MG symptoms temporarily (10-minute effect).

Diagnostic Methods After Discontinuation of Edrophonium Test

  1. Blood Tests for Antibodies: Including AChR, MuSK, and LRP4 antibodies.

  2. Electrophysiological Tests:

    • Repetitive nerve stimulation and single-fiber EMG to assess communication between nerves and muscles.

  3. Ice Pack Test: Useful specifically for ocular myasthenia gravis.

  4. CT or MRI: Used to check for thymoma.

Antibody Testing

  • Current First-Line Diagnostic Tools:

    1. AChR Antibodies: Present in approximately 85% of generalized MG cases.

    2. MuSK Antibodies: Found in some AChR-negative patients.

    3. LRP4 Antibodies: Detected in a smaller subset of patients.

    4. Current Research: Investigating agrin and other novel antibodies for seronegative MG.

Electrophysiological Testing

  • Studies Focused on Neuromuscular Transmission:

    • Repetitive Nerve Stimulation (RNS): Assesses decremental responses in muscle action potentials.

    • Single-Fiber Electromyography (SFEMG): The most sensitive test, detecting "jitter" in muscle fiber activation.

Ice Pack Test Protocol

  1. Procedure:

    • Baseline measurement of eyelid position.

    • Ice pack applied for 2–5 minutes.

    • Re-measure eyelid position after ice pack removal.

  2. Interpretation:

    • Positive result: Improvement of ≥2 mm in eyelid position indicates MG.

    • Mechanism: Cold exposure enhances neuromuscular transmission.

    • Specificity: Improvement is not observed in ptosis caused by other conditions.

Clinical Manifestations in Myasthenia Gravis

  • Respiratory Rate: Varies based on muscle paralysis severity.

    • Severe Cases: Possible apnea and cyanosis.

  • Chest Assessment Findings:

    • Diminished breath sounds

    • Presence of crackles and rhonchi.

Pulmonary Function Test Findings

  • Respective Findings for Moderate to Severe MG:

    • Forced Expiratory Volume and Flow Rate:

    • Results may show decreased values with normal variations.

    • Lung Volume & Capacity Findings:

    • All measured volumes (VT, IRV, ERV, RV, VC, IC, FRC, TLC) exhibit decrease, except RV/TLC ratio which remains the same.

    • MIP: Maximum inspiratory pressure decreases.

Arterial Blood Gases Findings

  • Associated with moderate to severe MG:

    • Can show acute ventilatory failure with hypoxemia and acute respiratory acidosis characterized by:

    • Decreased pH

    • Increased PaCO2

    • Normal HCO3-

    • Decreased PaO2

    • Decreased SaO2/SpO2

Chest X-ray (CXR)

  • Interpretation:

    • Normal or demonstrate increased opacity suggesting atelectasis or consolidation.

Respiratory Monitoring Parameters

  • Key Measurements:

    • Forced Vital Capacity (VC): Should be >10 ml/kg of ideal body weight.

    • Maximum Inspiratory Force (NIF): More than -20 cm H2O.

    • Maximum Expiratory Pressure (MEP): Greater than +40 cm H2O.

    • Continuous monitoring of blood pressure, oxygen saturation, and arterial blood gases.

  • Mechanical Ventilation: Should be initiated based on clinical data indicating impending or acute ventilatory failure.

Indicators of Impending Acute Ventilatory Failure

  • Critical Values:

    • FVC < 20 mL/kg

    • MIP/NIF < -30 cm H2O (inspiratory strength)

    • MEP < 40 cm H2O (expiratory strength)

    • pH < 7.35

    • PaCO2 > 45 mm Hg

Treatment Protocols for Myasthenia Gravis

  • Acetylcholinesterase Inhibitors:

    • Mechanism: Enhance ACh action by inhibiting its breakdown.

    • Pyridostigmine: First-line treatment effective in mild cases.

  • Corticosteroids and Immunosuppressive Drugs:

    • Considered for chronic management; can lead to serious side effects including diabetes and osteoporosis.

  • Thymectomy:

    • Surgical removal of the thymus gland, suspected to be the source of ACh receptor antibodies.

  • Plasmapheresis:

    • A blood filtering process to reduce ACh receptor antibodies rapidly.

  • Intravenous Immunoglobulin (IVIG):

    • Another rapid treatment option.

Treatment of Pyridostigmine

  • Uses:

    • Main treatment for managing muscle weakness caused by MG and for nerve gas exposure.

  • Mechanism:

    • Pyridostigmine is an acetylcholinesterase inhibitor; it increases ACh concentration, enhancing nerve-muscle communication.

Respiratory Care Treatment Protocols

  • Protocol Categories:

    • Oxygen Therapy Protocol

    • Bronchopulmonary Hygiene Therapy Protocol

    • Lung Expansion Therapy Protocol

    • Mechanical Ventilation Protocol

Notes

  • All treatment protocols must be tailored to individual patient needs and frequently assessed due to the episodic nature of the disease and varying patient responses.